Kairos Pharma reported total assets of $6.54M and total liabilities of $0.20M for the quarter ended Dec 2025, up 30.7% year over year. This balance sheet covers 9 quarters of results from Sep 2023 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Balance SheetBalance Sheet | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Current Assets | |||||||||
| Cash & EquivalentsCash & Equiv. | 0.10M | 0.09M | 3.22M | 1.27M | 3.62M | 3.03M | 4.49M | ||
| Cash & Current Investments | 0.10M | 0.09M | 3.22M | 1.27M | 3.62M | 3.03M | 4.49M | ||
| Prepaid Assets | 0.01M | 0.01M | 0.04M | 0.06M | 0.09M | 0.05M | |||
| Current Assets | 0.10M | 4.74M | 4.17M | 6.05M | 4.84M | 5.39M | |||
| Non-Current Assets | |||||||||
| Intangibles | 0.38M | 0.26M | 0.22M | 0.18M | 0.14M | 0.06M | |||
| Goodwill & Intangibles | 0.38M | 0.26M | 0.22M | 0.18M | 0.14M | 0.06M | |||
| Other Non-Current Assets | 0.48M | 1.38M | 1.71M | 1.69M | 1.09M | ||||
| Non-Current Assets | 0.86M | 0.26M | 1.60M | 1.89M | 1.83M | 1.15M | |||
| Assets | 0.97M | 5.00M | 5.77M | 7.94M | 6.67M | 6.54M | |||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payables | 2.40M | 1.53M | 0.99M | 0.81M | 0.68M | 0.20M | |||
| Notes Payables | 0.79M | ||||||||
| Payables | 2.40M | 2.32M | 0.99M | 0.81M | 0.68M | 0.20M | |||
| Accumulated Expenses | 0.04M | ||||||||
| Other Accumulated Expenses | 0.00M | ||||||||
| Total Current Liabilities | 2.41M | 1.67M | 0.99M | 0.81M | 0.68M | 0.20M | |||
| Non-Current Liabilities | |||||||||
| Convertible Debt | 0.64M | ||||||||
| Other Non-Current Liabilities | 0.00M | ||||||||
| Total Non-Current Liabilities | 3.04M | 1.67M | 0.99M | ||||||
| Total Liabilities | 3.04M | 1.67M | 0.99M | 0.81M | 0.68M | 0.20M | |||
| Shareholder's Equity | |||||||||
| Total Debt | 0.79M | ||||||||
| Common Equity | -1.87M | -2.08M | -2.40M | -2.65M | 3.33M | 4.78M | 7.13M | 6.00M | 6.34M |
| Liabilities and Shareholders Equity | 0.97M | 5.00M | 5.77M | 7.94M | 6.67M | 6.54M | |||
| Retained Earnings | -6.21M | -7.84M | -8.82M | -10.08M | -11.50M | -14.26M |
Pull Kairos Pharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=KAPA&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "KAPA", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=KAPA&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();